Aventis Behring Zemaira approval
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Aventis Behring plans to launch its alpha-1 proteinase inhibitor Zemaira before the end of September. FDA approved the biologic July 8 for use as chronic augmentation and maintenance therapy in individuals with A1-PI deficiency and clinical evidence of emphysema. Aventis will use 50 internal sales reps, but is looking to bolster promotions with an external distribution partner. The fast-track product was submitted in January and received a priority review. Zemaira is the third AI-PI to clear FDA, following Bayer's Prolastin and Baxter's Aralast...
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.